MedTrace Logo

Deep sequencIng in Cutaneous Squamous CEll caRciNomas

NCT05878288 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2024-11-21

No results posted yet for this study

Summary

To comprehensively describe the molecular profile of the tumour ecosystem of cutaneous squamous cell carcinoma (CSCC) patients treated with neoadjuvant immunotherapy using single-cell sequencing and bulk genomic profiling.

Conditions

Interventions

DRUG

Cemiplimab

Cemiplimab 50 mg/mL supplied as a sterile liquid in single-use glass vials.

Sponsors & Collaborators

Principal Investigators

  • Annette M Lim, MBBS, FRACP, PhD · Peter MacCallum Cancer Centre, Australia

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2029-05-31
Completion
2029-05-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05878288 on ClinicalTrials.gov